-
Mashup Score: 0Cystic fibrosis triple therapy likely contributed to exacerbation decrease during pandemic - 2 year(s) ago
A new study highlighted a decrease in pulmonary exacerbations during the COVID-19 pandemic among patients with cystic fibrosis receiving triple therapy with elexacaftor/tezacaftor/ivacaftor.“Highly effective elexacaftor/tezacaftor/ivacaftor therapy likely contributed to a considerable decrease in documented exacerbations beyond that attributable to the COVID-19 pandemic and the observed
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Cystic fibrosis triple therapy likely contributed to exacerbation decrease during pandemic - 2 year(s) ago
A new study highlighted a decrease in pulmonary exacerbations during the COVID-19 pandemic among patients with cystic fibrosis receiving triple therapy with elexacaftor/tezacaftor/ivacaftor.“Highly effective elexacaftor/tezacaftor/ivacaftor therapy likely contributed to a considerable decrease in documented exacerbations beyond that attributable to the COVID-19 pandemic and the observed
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
A presentation at #NACFC2021 found that #cysticfibrosis triple therapy may have contributed to #pulmonaryexacerbation reductions during #COVID19. @CF_Foundation @InfectDisNews https://t.co/pWMpzvBW4o
-
-
Mashup Score: 0Cystic fibrosis triple therapy likely contributed to exacerbation decrease during pandemic - 2 year(s) ago
A new study highlighted a decrease in pulmonary exacerbations during the COVID-19 pandemic among patients with cystic fibrosis receiving triple therapy with elexacaftor/tezacaftor/ivacaftor.“Highly effective elexacaftor/tezacaftor/ivacaftor therapy likely contributed to a considerable decrease in documented exacerbations beyond that attributable to the COVID-19 pandemic and the observed
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
A presentation at #NACFC2021 found that #cysticfibrosis triple therapy may have contributed to #pulmonaryexacerbation reductions during #COVID19. @CF_Foundation @InfectDisNews https://t.co/hNY2tx3LKM
-
-
Mashup Score: 0Cystic fibrosis triple therapy likely contributed to exacerbation decrease during pandemic - 2 year(s) ago
A new study highlighted a decrease in pulmonary exacerbations during the COVID-19 pandemic among patients with cystic fibrosis receiving triple therapy with elexacaftor/tezacaftor/ivacaftor.“Highly effective elexacaftor/tezacaftor/ivacaftor therapy likely contributed to a considerable decrease in documented exacerbations beyond that attributable to the COVID-19 pandemic and the observed
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
A presentation at #NACFC2021 found that #cysticfibrosis triple therapy may have contributed to #pulmonaryexacerbation reductions during #COVID19. @CF_Foundation @InfectDisNews https://t.co/rkq0XzV79B
-
-
Mashup Score: 0NACFC - 3 year(s) ago
The latest news from NACFC, with physician perspective, researcher interviews and insight on cystic fibrosis.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Don't forget that Healio #Pulmonology will be covering the virtual #NACFC2021 from November 2-5. To stay up to date, be sure to check out our coverage of last year's North American #CysticFibrosis Conference below: https://t.co/veGwGYX7mO
-
-
Mashup Score: 0NACFC - 3 year(s) ago
The latest news from NACFC, with physician perspective, researcher interviews and insight on cystic fibrosis.
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Don't forget that Healio #Pulmonology will be covering the virtual #NACFC2021 from November 2-5. To stay up to date, be sure to check out our coverage of last year's North American #CysticFibrosis Conference below: https://t.co/veGwGYX7mO
-
A presentation at #NACFC2021 found that #cysticfibrosis triple therapy may have contributed to #pulmonaryexacerbation reductions during #COVID19. @CF_Foundation @InfectDisNews https://t.co/pWMpzvBW4o